Date:

Location:

Speakers:

On the Verge of a Biologics Golden Age
David Meininger, Ph.D.
Executive Director, Merck
Click here to download presentation

pH Switch Antibodies, Bispecific IgG, and Site-specific ADC: Antibody Engineering to Address Novel Biological Questions
Arvind Rajpal, Ph.D.
VP of Protein Engineering, Rinat-Pfizer
Not available for download.

Proteomic Identification of Cancer Targets for the Development of Novel Antibody Drug Conjugates
Thi-Sau Migone, Ph.D.
Chief Scientific Officer, Igenica
Not available for download.

Technology Highlights- From Sequence to Gram Scale Antibody in less than 6 Weeks 
Adam Adler, Ph.D.
Director, Research Collaborations, LakePharma
Click here to download presentation

Production of Homogeneous ADCs with Combination Warheads and Bispecifics using an Open Cell Free System
Aaron Sato, Ph.D.
VP of Research, Sutro Biopharma
Click here to download presentation

Optimization of Protein Therapeutics by Mammalian Cell Display and Deep Sequencing
Yoshiko Akamatsu, Ph.D.
Principal Research Scientist, Abbvie
Not available for download.

Process Evolution from the Iron Age to the New Age
Jon Gingrich
Manager- Business Development, Avid Bioservices
Click here to download presentation

Protecting Advances in Antibody Technology
Atulya Agarwal, Ph.D., J.D.
Partner, Dickstein Shapiro
Click here to download presentation 

Schedule:

8:00 AM - 8:45 AM
Breakfast and Registration

9:00 AM
Welcome Remarks

9:05 AM - 9:50 AM
On the Verge of a Biologics Golden Age
David Meininger, Ph.D.
Executive Director, Merck

9:50 AM - 10:35 AM
pH Switch Antibodies, Bispecific IgG, and Site-specific ADC: Antibody Engineering to Address Novel Biological Questions
Arvind Rajpal, Ph.D.
VP of Protein Engineering, Rinat-Pfizer

10:35 AM - 10:50 AM
Morning Break

10:50 AM - 11:30 AM
Proteomic Identification of Cancer Targets for the Development of Novel Antibody Drug Conjugates
Thi-Sau Migone, Ph.D.
Chief Scientific Officer, Igenica

11:30 AM - 12:00 PM
Technology Highlights- From Sequence to Gram Scale Antibody in less than 6 Weeks
Adam Adler, Ph.D.
Director, Research Collaborations, LakePharma, Inc.

12:00 PM - 1:30 PM
Lunch

1:30 PM - 2:15 PM
Production of Homogeneous ADCs with Combination Warheads and Bispecifics using an Open Cell Free System
Aaron Sato, Ph.D.
VP of Research, Sutro Biopharma

2:15 PM - 3:00 PM
Optimization of Protein Therapeutics by Mammalian Cell Display and Deep Sequencing
Yoshiko Akamatsu, Ph.D.
Principal Research Scientist, Abbvie

3:00 PM - 3:30 PM
Afternoon Break

3:30 PM - 4:00 PM
Process Evolution from the Iron Age to the New Age
Jon Gingrich
Manager- Business Development, Avid Bioservices

4:00 PM - 4:30 PM
Protecting Advances in Antibody Technology
Atulya Agarwal, Ph.D., JD
Partner, Dickstein Shapiro

Registration:

Registration for this year is not open yet, please check later.

Sponsors: